A Daily Pill Grew Children With Achondroplasia Faster Than Placebo in a Phase III Trial
In PROPEL 3, published in the New England Journal of Medicine, 114 children with achondroplasia on daily oral infigratinib grew 5.96 cm a year against 4.22 cm on placebo — a 1.74 cm annual difference, with no drug-related serious adverse events. BridgeBio holds a February 4, 2027 PDUFA date; approval would make it the first oral therapy for a condition whose approved treatments are all injections.